Stock Research Monitor: IOVA, JAGX, and JAZZ
LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. WallStEquities.com shifts focus on the Biotechnology sector, which harnesses biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). All you have to do is sign up today for this free limited time offer by clicking the link below.
Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98. A total volume of 5.27 million shares was traded, which was above their three months average volume of 1.33 million shares. The Company's shares have gained 21.10% over the previous three months. The stock is trading below its 200-day moving average by 7.94%. Additionally, shares of Intrexon, which operates in the synthetic biology field in the US, have a Relative Strength Index (RSI) of 29.64.
On May 10th, 2018, Intrexon announced its Q1 results for 2018. Total revenues for the quarter were $43.8 million, net loss attributable to the Company was $42.0 million, and adjusted EBITDA was $(19.7) million. At March 31st, 2018, cash, cash equivalents, and short-term investments totaled $120.2 million, the value of preferred shares totaled $166.1 million, and the value of common equity securities totaled $14.0 million. Get the full research report on XON for free by clicking below at:
Shares in San Carlos, California headquartered Iovance Biotherapeutics Inc. ended at $15.20, up 2.36% from the last trading session. The stock recorded a trading volume of 723,868 shares. The Company's shares have surged 151.24% over the past year. The stock is trading 41.15% above its 200-day moving average. Moreover, shares of Iovance Biotherapeutics, which focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells, have an RSI of 50.41.
On May 02nd, 2018, Iovance Biotherapeutics announced that its management will present at the UBS Global Healthcare Conference on May 21st, 2018, at 2:30 p.m. ET in New York. A live, audio webcast of the presentation will be available under the Investors section of the Company's website. IOVA's complimentary research coverage is a few simple steps away at:
On Friday, shares in San Francisco, California-based Jaguar Health Inc. recorded a trading volume of 1.24 million shares. The stock rose slightly by 0.37%, closing the day at $0.16. The Company's shares have gained 15.29% over the previous three months. The stock is trading 12.12% below its 50-day moving average. Additionally, shares of Jaguar Health, which focuses on developing novel, sustainably derived gastrointestinal products for human prescription use and animals worldwide, have an RSI of 37.74.
On April 19th, 2018, Jaguar Health announced an update regarding the US AIDS Drug Assistance Programs (ADAPs). Mytesi® (crofelemer), the Company's first-in-class anti-secretory prescription drug approved by the US FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, is currently on 22 state ADAP formularies and is under review by other state ADAPs. Register for your free research report on JAGX at:
At the close of trading on Friday, shares in Dublin, Ireland headquartered Jazz Pharmaceuticals PLC recorded a trading volume of 1.09 million shares, which was higher than their three months average volume of 435,740 shares. The stock finished the session 2.07% higher at $164.42. The Company's shares have gained 5.09% in the past month, 17.50% in the previous three months, and 5.95% over the past year. The stock is trading above its 50-day and 200-day moving averages by 8.44% and 12.78%, respectively. Furthermore, shares of Jazz Pharma have an RSI of 67.10.
On May 08th, 2018, Jazz Pharma announced its results for Q1 2018. GAAP net income for Q1 2018 was $46.0 million; total revenues were $444.6 million; GAAP SG&A expenses were $207.2 million; and GAAP R&D expenses were $62.7 million. As of March 31st, 2018, cash, cash equivalents, and investments were $708.2 million, and the outstanding principal balance of the Company's long-term debt was $1.8 billion. Wall St. Equities' downloadable research report on JAZZ available at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities